MarketCap
Regeneron Pharmaceuticals REGN
$ 803.48
1.0%
Facebook
X
Telegram
Regeneron Pharmaceuticals Financial Ratios 2025-2007 | REGN
Brief overview of Regeneron Pharmaceuticals's financial ratios
This overview follows the five latest available observations from 2021 through 2025.
The valuation comparison uses P/E 18.04x (median 18.04x), EV/EBITDA 7.63x (median 14.5x), P/S 5.67x (median 5.67x). The combined ratio level is close to the company's five-year norm at a -2.1% deviation. No clear premium or discount is visible.
Earnings yield calculated as 1/P/E is about 5.5%, showing current profit per unit of share price.
Current measures of operating quality are ROE 14.4%, ROA 11.1%, ROCE 11.4%. Fundamental efficiency is balanced: profitability supports valuation but does not remove the need for future growth.
Price, earnings and growth produce a PEG of 1.08x, a neutral level if forecasts are realistic.
A longer cycle, from 103.9 days to 152.1 days, indicates slower release of cash from operations.
What the ratios show
Regeneron Pharmaceuticals's profile looks neutral, with price and fundamental efficiency broadly aligned.
Annual Financial Ratios Regeneron Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
18.0 | 17.6 | 25.3 | 19.3 | 8.3 | 14.8 | 17.4 | 18.5 | 33.7 | 40.3 | 68.1 | 120.4 | 67.6 | 22.1 | -36.3 | -22.0 | -18.1 | - | - |
P/S |
5.7 | 5.5 | 7.6 | 6.9 | 4.2 | 6.1 | 4.7 | 6.8 | 6.9 | 7.4 | 10.6 | 14.9 | 13.6 | 12.0 | 18.1 | 5.0 | 3.2 | - | - |
EPS |
43.1 | 40.9 | 37.0 | 40.5 | 76.4 | 32.6 | 19.4 | 22.6 | 11.3 | 8.6 | 6.2 | 3.4 | 4.2 | 7.9 | -2.5 | -1.3 | -0.8 | - | - |
EV (Enterprise Value) |
87.4 B | 83.6 B | 105 B | 87.1 B | 70.5 B | 55.9 B | 38.8 B | 46.8 B | 42.2 B | 38.1 B | 44.4 B | 42.6 B | 29.2 B | 17.2 B | 8.41 B | 2.74 B | 1.37 B | -248 M | -499 M |
EBITDA per Share |
39.4 | 41.5 | 41.9 | 47.4 | 87.3 | 35.4 | 22.2 | 24.9 | 20.9 | 13.7 | 12.9 | 8.86 | 8.18 | 5.22 | -1.92 | -0.94 | -0.76 | - | - |
EV/EBITDA |
21.2 | 18.7 | 23.4 | 17.1 | 7.6 | 13.9 | 14.5 | 16.3 | 17.8 | 24.8 | 32.0 | 46.5 | 35.5 | 33.6 | -45.1 | -35.3 | -22.8 | 3.3 | - |
PEG |
1.08 | 0.6 | 0.92 | 0.57 | 0.15 | 0.58 | -1.2 | 0.18 | 1.06 | 1.04 | 0.87 | -5.99 | -1.49 | 0.05 | 0.38 | - | - | - | - |
P/B |
2.6 | 2.6 | 3.9 | 3.7 | 3.6 | 4.7 | 3.3 | 5.2 | 6.6 | 8.1 | 11.8 | 16.5 | 14.7 | 13.3 | 16.6 | 4.3 | 3.1 | - | - |
P/CF |
16.3 | 17.6 | 21.8 | 16.7 | 9.4 | 19.9 | 18.4 | 25.0 | 39.0 | 37.5 | 66.3 | 102.2 | 67.1 | -133.5 | -40.5 | 23.1 | -17.6 | - | - |
ROE % |
14.41 | 15.03 | 15.22 | 19.14 | 43.03 | 31.86 | 19.08 | 27.91 | 19.51 | 20.13 | 17.40 | 13.69 | 21.74 | 60.24 | -45.65 | -19.79 | -17.10 | -18.77 | - |
ROA % |
11.11 | 11.69 | 11.95 | 14.85 | 31.75 | 20.47 | 14.29 | 20.83 | 13.67 | 12.84 | 11.34 | 8.99 | 14.38 | 36.06 | -16.75 | -9.59 | -9.15 | - | - |
ROCE % |
11.45 | 13.60 | 15.58 | 20.91 | 47.67 | 32.44 | 17.39 | 24.63 | 27.26 | 23.22 | 26.09 | 26.06 | 28.66 | 23.88 | -17.46 | -18.47 | -18.68 | -20.46 | - |
Current Ratio |
4.4 | 4.5 | 4.7 | 4.5 | 3.8 | 2.8 | 3.7 | 4.5 | 3.8 | 2.6 | 3.6 | 3.3 | 6.0 | 7.4 | 4.4 | 1.9 | 2.2 | - | - |
DSO |
152.1 | 152.7 | 153.0 | 170.4 | 103.9 | 111.9 | 124.0 | 122.0 | 122.7 | 121.0 | 130.6 | 131.7 | 154.7 | 183.5 | 84.4 | 2.1 | 1.4 | - | - |
DIO |
- | - | - | - | - | - | 660.5 | 968.0 | 667.5 | 486.4 | 221.7 | 229.4 | 165.3 | 123.8 | 1173.6 | - | - | - | - |
DPO |
- | - | - | - | - | - | 195.1 | 183.5 | 163.8 | 164.4 | 131.0 | 177.2 | 145.5 | 168.3 | 2401.2 | - | - | - | - |
Operating Cycle |
152.1 | 152.7 | 153.0 | 170.4 | 103.9 | 111.9 | 784.6 | 1090.0 | 790.2 | 607.4 | 352.3 | 361.1 | 319.9 | 307.3 | 1258.0 | 2.1 | 1.4 | - | - |
Cash Conversion Cycle |
152.1 | 152.7 | 153.0 | 170.4 | 103.9 | 111.9 | 589.5 | 906.5 | 626.4 | 443.0 | 221.3 | 184.0 | 174.4 | 139.0 | -1143.3 | 2.1 | 1.4 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Regeneron Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
12.62 | 6.99 | 14.09 | 13.24 | 7.58 | 12.4 | 13.25 | 6.7 | 9.48 | 9.05 | 7.64 | - | 12.31 | 7.9 | 9.12 | - | 15.37 | 29.51 | 10.58 | 10.9 | 7.98 | 8.19 | 5.69 | 7.25 | 6.12 | 1.77 | 4.23 | 7.58 | 5.5 | 5.12 | 4.44 | 1.62 | 3.64 | 3.66 | 2.36 | 2.41 | 2.53 | 1.88 | 1.74 | 1.49 | 2.04 | 1.89 | 0.74 | 0.89 | 0.89 | 0.89 | 0.89 | 0.98 | 1.44 | 0.89 | 1.02 | 4.92 | 2.02 | 0.81 | 0.12 | -0.58 | -0.68 | -0.69 | -0.49 | - | - |
EBITDA per Share |
15 | 7.37 | 13.8 | - | 6.73 | - | - | 8.03 | - | - | 9.77 | - | 13.7 | 10.3 | 12.5 | - | 19.4 | 31.9 | 11.2 | - | 11.6 | 7.04 | 6.89 | - | 8.18 | 3.83 | 4.88 | - | 6.78 | 6.42 | 5.61 | - | 6.29 | 5.88 | 4.44 | - | 4.18 | 3.25 | 3.38 | - | 4.3 | 3.66 | 2.93 | - | 8.56 | 2.39 | 2.3 | - | 2.72 | 1.81 | 1.68 | - | 2.42 | 1.11 | 0.33 | - | -0.39 | -0.5 | -0.38 | -0.23 | -0.19 |
ROE % |
15.77 | 14.43 | 16.69 | 17.05 | 15.08 | 16.37 | 15.83 | 14.23 | 17.70 | 17.77 | 18.62 | 15.14 | 24.60 | 38.95 | 44.14 | 39.25 | 49.68 | 47.86 | 35.51 | 31.86 | 28.58 | 26.98 | 20.59 | 19.08 | 21.31 | 22.06 | 26.61 | 27.91 | 21.37 | 20.90 | 20.91 | 19.50 | 22.37 | 22.00 | 20.10 | 20.13 | 18.68 | 18.48 | 19.40 | 17.40 | 16.70 | 14.47 | 12.68 | 14.11 | 15.51 | 19.21 | 20.16 | 21.71 | 54.21 | 62.35 | 64.04 | 59.91 | 11.47 | -16.74 | -35.77 | -45.65 | -44.38 | -38.41 | -8.94 | -9.73 | -6.86 |
ROA % |
12.16 | 11.21 | 13.01 | 13.34 | 11.80 | 12.78 | 12.36 | 11.11 | 13.77 | 14.33 | 18.06 | 15.34 | 29.77 | 25.01 | 31.29 | 27.59 | 34.29 | 32.30 | 23.11 | 20.47 | 19.12 | 18.74 | 14.82 | 14.29 | 15.93 | 16.48 | 19.87 | 20.83 | 15.82 | 15.18 | 14.91 | 13.67 | 15.32 | 14.69 | 13.08 | 12.84 | 11.98 | 11.93 | 12.59 | 11.34 | 10.92 | 9.52 | 8.40 | 9.36 | 10.29 | 12.73 | 13.34 | 14.38 | 33.71 | 38.12 | 38.85 | 36.06 | 9.41 | -4.50 | -12.91 | -16.75 | -16.31 | -14.82 | -3.28 | -3.59 | -3.22 |
ROCE % |
13.05 | 10.98 | 12.96 | 13.43 | 12.61 | 15.06 | 15.27 | 15.51 | 18.43 | 19.33 | 21.42 | 17.39 | 28.10 | 44.51 | 48.44 | 42.12 | 51.67 | 46.92 | 31.15 | 21.86 | 28.51 | 21.81 | 20.18 | 13.83 | 20.99 | 21.44 | 25.07 | 20.74 | 29.85 | 31.65 | 31.55 | 25.08 | 33.23 | 30.67 | 29.12 | 22.11 | 32.85 | 34.13 | 35.33 | 27.93 | 36.39 | 57.96 | 56.99 | 57.65 | 61.32 | 37.11 | 36.49 | 28.07 | 44.32 | 39.21 | 32.90 | 25.06 | 13.02 | -15.65 | -31.11 | -32.89 | -42.11 | -36.47 | -8.44 | -9.22 | -6.39 |
Current Ratio |
4.2 | 4.3 | 4.4 | 4.6 | 4.6 | 4.6 | 4.6 | 4.7 | 4.4 | 4.6 | 4.6 | 4.5 | 4.4 | - | 4.1 | 3.8 | 3.7 | 3.4 | 3.1 | 2.8 | 2.8 | 2.8 | 2.8 | 4.0 | 4.0 | 4.0 | 4.0 | 3.9 | 3.9 | 3.9 | 3.9 | 3.3 | 3.3 | 3.3 | 3.3 | 2.8 | 2.8 | 2.8 | 2.8 | 2.9 | 2.9 | 2.9 | 2.9 | 3.0 | 3.0 | 3.0 | 2.9 | 3.0 | 3.0 | 3.0 | 3.0 | 2.5 | 2.5 | 2.5 | 2.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.9 |
DSO |
130.8 | 144.5 | 137.3 | 138.7 | 175.8 | 145.0 | 140.7 | 156.8 | 145.3 | 147.9 | 150.7 | - | 86.2 | 77.3 | 167.3 | - | 164.5 | 99.2 | 149.5 | 155.0 | 163.7 | 192.3 | 155.1 | 102.8 | 109.9 | 121.5 | 127.1 | 81.6 | 94.5 | 97.8 | 98.5 | 88.7 | 93.6 | 95.5 | 99.7 | 99.9 | 100.5 | 101.1 | 94.8 | 95.8 | 92.5 | 105.3 | 99.3 | 84.1 | 93.0 | 101.3 | 111.3 | 117.7 | 120.3 | 156.9 | 143.2 | 130.6 | 126.6 | 177.8 | 122.3 | 21.0 | 25.1 | 23.9 | 12.7 | 3.1 | - |
Operating Cycle |
- | 143.5 | - | 138.7 | 175.8 | 145.0 | 140.7 | 156.8 | 145.3 | 147.9 | 150.7 | - | 86.2 | 77.3 | 167.3 | - | 164.5 | 99.2 | 149.5 | 155.0 | 163.7 | 192.3 | 155.1 | 102.8 | 109.9 | 121.5 | 127.1 | 81.6 | 94.5 | 97.8 | 98.5 | 88.7 | 93.6 | 95.5 | 99.7 | 99.9 | 100.5 | 101.1 | 94.8 | 95.8 | 92.5 | 105.3 | 99.3 | 84.1 | 93.0 | 101.3 | 111.3 | 117.7 | 120.3 | 156.9 | 143.2 | 130.6 | 126.6 | 177.8 | 122.3 | 21.0 | 25.1 | 23.9 | - | - | - |
Cash Conversion Cycle |
- | 143.5 | - | 138.7 | 175.8 | 145.0 | 140.7 | 156.8 | 145.3 | 147.9 | 150.7 | - | 86.2 | 77.3 | 167.3 | - | 164.5 | 99.2 | 149.5 | 155.0 | 163.7 | 192.3 | 155.1 | 102.8 | 109.9 | 121.5 | 127.1 | 81.6 | 94.5 | 97.8 | 98.5 | 88.7 | 93.6 | 95.5 | 99.7 | 99.9 | 100.5 | 101.1 | 94.8 | 95.8 | 92.5 | 105.3 | 99.3 | 84.1 | 93.0 | 101.3 | 111.3 | 117.7 | 120.3 | 156.9 | 143.2 | 130.6 | 126.6 | 177.8 | 122.3 | 21.0 | 25.1 | 23.9 | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Regeneron Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
